Skip to main navigation Skip to search Skip to main content

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial

  • GBP510/AS03 study group

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology